Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
26 Results for "
2.2.15 cells
" in MedChemExpress (MCE) Product Catalog:
Products (26)
26 Results for "2.2.15 cells" in MCE Product Catalog:
2
Target:
Research Areas:
Adefovir (GS-0393) is an adenosine monophosphate analog antiviral agent that after intracellular conversion to Adefovir diphosphate inhibits HBV DNA polymerase. Adefovir has an IC50 of 0.7 μM against HBV in the HepG2.2.15 cell line. Adefovir has good antiviral activity against several viruses, including HBV and herpesviruses .
1
1 Cited Publications
Cat. No.: HY-N3239
CAS No.: 87085-00-5
Category:
1
Research Areas:
Dimethyl biphenyl-4,4'-dicarboxylate (Biphenyl dimethyl dicarboxylate) is a hepatoprotective agent. Dimethyl biphenyl-4,4'-dicarboxylate stimulates the Jak/Stat signaling pathway and induces the expression of IFN-α-stimulated genes, particularly 6-16 and ISG12. Dimethyl biphenyl-4,4'-dicarboxylate inhibits the replication of pregenomic RNA and HBeAg. Polymer micelles loaded with Dimethyl biphenyl-4,4'-dicarboxylate can serve as carriers for the compound. Dimethyl biphenyl-4,4'-dicarboxylate can be used as an auxiliary improving agent for chronic hepatitis. Dimethyl biphenyl-4,4'-dicarboxylate is applicable to research related to chronic hepatitis B .
1
Helioxanthin derivative 5-4-2 is an analogue of helioxanthin, exhibites significant in vitro anti-HBV activity with EC50 of 0.08 uM in HepG2.2.15 cells.
SAG-524 is a potent oral small molecule HBV viral replication inhibitor. SAG-524 decreased HBV-DNA and HbsAg levels in supernatant of HepG2.2.15 cells, IC50 0.92 and 1.4 nM, respectively .
Cat. No.: HY-N4168
CAS No.: 123483-19-2
Category:
other families Simple Phenylpropanols Other Diseases Phenols Polyphenols Phenylpropanoids Plants Disease Research Fields
Target:
Cat. No.: HY-N1323
CAS No.: 1351931-30-0
Category:
Target:
HBF-0259 is a potent and selective inhibitor of hepatitis B virus (HBV) surface antigen (HBsAg) secretion, with an EC50 of 1.5 μM in HepG2.2.15 cells. HBF-0259 has no effect on HBV DNA synthesis .
Cat. No.: HY-N11792
CAS No.: 1283600-08-7
Target:
Cat. No.: HY-N2882
CAS No.: 133538-77-9
Target:
Cat. No.: HY-W754691
CAS No.: 6808-72-6
Target:
Cat. No.: HY-N3094
CAS No.: 1025023-04-4
Cat. No.: HY-N3093
CAS No.: 1025023-05-5
Synonyms: (+)-Periglaucine B
Target:
Cat. No.: HY-119702
CAS No.: 1835652-66-8
YZ51 is a derivative of Osalmid (HY-B2116) with stronger ribonucleotide reductase (RR) inhibitory activity and HBV replication inhibition ability than Osalmid. The IC50 of YZ51 against recombinant RR activity is 0.6 μM, and the IC50 against HepG2.2.15 cell RR activity is 23.7 μM .
Cat. No.: HY-116607
CAS No.: 246872-58-2
BAY38-7690 is a non-nucleoside inhibitor that inhibits HBV replication. BAY38-7690 inhibits viral DNA replication by preventing the formation of viral core particles (nucleocapsids). The IC50 value of BAY38-7690 against HBV in stably transfected HepG2.2.15 cells is 0.15 μM .
Cat. No.: HY-117999
CAS No.: 247037-81-6
BAY39-5493 is a non-nucleoside inhibitor that inhibits HBV replication. BAY39-5493 inhibits viral DNA replication by preventing the formation of viral core particles (nucleocapsids). The IC50 value of BAY39-5493 against HBV in stably transfected HepG2.2.15 cells is 0.03 μM .
Cat. No.: HY-N12105
CAS No.: 1015175-06-0
Target:
Cat. No.: HY-B1826S2
CAS No.: 1190021-70-5
Synonyms: GS-0393-d4; PMEA-d4
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
